阿帕替尼联合NP化疗治疗晚期非小细胞肺癌疗效及对患者血清肿瘤标志物和生存质量的影响  

Effect of Apatinib Combined with NP Chemotherapy on Serum Tumor Markers and Quality of Life in Patients with Advanced Non-small Cell Lung Cancer

作　　者：常英英 郭克锋 王坤[1] 刘红丽[1] 薛艳萍 高慧芳 Chang Yingying;Guo Kefeng;Wang Kun;Liu Hongli;Xue Yanping;Gao Huifang(Department of Laboratory, Henan Sanmenxia Yellow River Hospital, Henan Sanmenxia 472000, China;Department of Oncology , Henan Sanmenxia Yellow River Hospital, Henan Sanmenxia 472000, China;Department of General Surgery, Henan Sanmenxia Yellow River Hospital, Henan Sanmenxia 472000, China)

机构地区：[1]三门峡黄河医院检验科,河南三门峡472000 [2]三门峡黄河医院肿瘤科,河南三门峡472000 [3]三门峡黄河医院普外科,河南三门峡472000

出　　处：《中国药师》2019年第10期1868-1870,共3页China Pharmacist

摘　　要：目的:探讨阿帕替尼联合NP化疗治疗晚期非小细胞肺癌疗效及对患者血清肿瘤标志物和生存质量影响。方法:晚期非小细胞肺癌患者113例随机分为观察组57例与对照组56例。对照组患者采用NP化疗方案治疗,观察组在对照组基础上加用阿帕替尼治疗。两组疗程均为4个化疗周期,每个周期28 d。比较两组近期疗效、生活质量改善和不良反应发生情况,及治疗前后血清肿瘤标志物变化。结果:观察组总有效率为56.14%,生存质量提高率为71.93%,均明显高于对照组(P<0.05)。两组治疗后血清癌抗原125(CA125)、癌胚抗原(CEA)和细胞角蛋白19片段(CYFRA21-1)水平均较治疗前明显降低(P<0.05),且观察组低于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论:晚期非小细胞肺癌患者应用阿帕替尼联合NP化疗治疗疗效明显,且可降低血清肿瘤标志物CA125、CEA和CYFRA21-1水平及提高患者生存质量,值得临床借鉴。Objective: To investigate the clinical effect of apatinib combined with NP chemotherapy on advanced non-small cell lung cancer( NSCLC) and its influence on serum tumor markers and quality of life( QOL). Methods: Totally 113 patients with advanced non-small cell lung cancer admitted to our hospital from March 2016 to March 2018 were randomly divided into the observation group( 57 cases) and the control group( 56 cases). The patients in the observation group were given apatinib combined with NP chemotherapy,while those in the control group were only given NP chemotherapy. The two groups were treated for 4 cycles of chemotherapy with 28 day for one cycle. The short-term efficacy,improvement of QOL,occurrence of toxic and side effects,and changes of serum tumor markers before and after the treatment were compared between the groups. Results: The total effective rate of the observation group( 56. 14%) was higher than that( 37. 50%) of the control group( P < 0. 05). The improvement rate of the QOL in the observation group( 71. 93%) was higher than that( 53. 57%) in the control group( P < 0. 05). After the treatment,the serum levels of CA125,CEA and CYFRA21-1 in the two groups were lower than those before the treatment( P < 0. 05);after the treatment,the serum levels of CA125,CEA and CYFRA21-1 in the observation group were lower than those in the control group( P < 0. 05). There was no significant difference in the incidence of nausea and vomiting,diarrhea,myelosuppression and rash between the groups( P > 0. 05).Conclusion: Apatinib combined with NP chemotherapy has obvious clinical effect in advanced non-small cell lung cancer patients,and can reduce serum tumor markers( CA125,CEA and CYFRA22-1) levels and improve the QOL of patients,which is worthy of clinical reference.

关 键 词：阿帕替尼 NP化疗方案 晚期非小细胞肺癌 疗效 肿瘤标志物 生存质量 

分 类 号：R979.12[医药卫生—药品]